FDA sends warning letter to RTI Biologics for 'deviations' from regulations The FDA posted an October 19 warning letter sent to RTI Biologics, citing "significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products."
News For RTIX From The Last 14 Days
Check below for free stories on RTIX the last two weeks.